March 27, 2012 – Confirmation of Orphan Drug Designation for the Use of Fluoxetine for the Treatment of Autism

Posted by on Mar 27, 2012 in Press Release | 0 comments

Autism Therapeutics announced today that it has received confirmation from the Office of Orphan Drug Products that the Company’s Orphan Drug Designation for the treatment of repetitive behaviors in autism (autistic disorder) remains in good standing.

AT Press Release March 27 2012 (ODD Confirmation)